ArticleCancers2020

HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma.

Laura Hüser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.